Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 2/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 7/20 | 0.36 |
| ▸ | JAK3 | P52333 | 6/20 | 0.36 |
| ▸ | HRH1 | P35367 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 2/20 | 0.33 |
| ▸ | HTR2C | P28335 | 2/20 | 0.33 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.32 |
| ▸ | GRM5 | P41594 | 1/20 | 0.32 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.32 |
| ▸ | MUSK | O15146 | 1/20 | 0.32 |
| ▸ | LCK | P06239 | 1/20 | 0.32 |
| ▸ | RET | P07949 | 1/20 | 0.32 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.32 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.32 |
| ▸ | CDK2 | P24941 | 1/20 | 0.32 |
| ▸ | FLT3 | P36888 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL347080 | 1.00 | APLNR (0.53) | APLNRHDAC6JAK2JAK3HRH1 | |
| SCHEMBL588810 | 1.00 | APLNR (0.53) | APLNRHDAC6JAK2JAK3HRH1 | |
| Hydrochloric Acid SCHEMBL3230301 | 0.98 | APLNR (0.51) | APLNRHDAC6JAK2JAK3HRH1 | |
| Hydrochloric Acid SCHEMBL3230070 | 0.98 | APLNR (0.51) | APLNRHDAC6JAK2JAK3HRH1 | |
| Hydrochloric Acid SCHEMBL1693822 | 0.98 | APLNR (0.51) | APLNRHDAC6JAK2JAK3HRH1 | |
| Hydrochloric Acid SCHEMBL454779 | 0.98 | APLNR (0.51) | APLNRHDAC6JAK2JAK3HRH1 | |
| Hydrochloric Acid SCHEMBL14672602 | 0.98 | APLNR (0.51) | APLNRHDAC6JAK2JAK3HRH1 | |
| Hydrochloric Acid SCHEMBL22159037 | 0.83 | APLNR (0.40) | APLNRHDAC6MAOB | |
| Hydrochloric Acid SCHEMBL22159035 | 0.83 | APLNR (0.40) | APLNRHDAC6MAOB | |
| SCHEMBL179299 | 0.82 | APLNR (0.51) | APLNRHDAC6JAK2JAK3HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260124204-A1 | METALLOENZYME INHIBITOR COMPOUNDS | EIKONIZO THERAPEUTICS, INC. (US) | 2026-05-07 | — | — | US | disclosed |
| US-20250352549-A1 | SUBSTITUTED HETEROCYCLIC COMPOUND DERIVATIVES AND THEIR PHARMACEUTICAL USE | AVELOS THERAPEUTICS INC. (KR) | 2025-11-20 | — | — | US | disclosed |
| EP-4634192-A1 | SUBSTITUTED HETEROCYCLIC COMPOUND DERIVATIVES AND THEIR PHARMACEUTICAL USE | Avelos Therapeutics Inc. (KR) | 2025-10-22 | — | — | EP | disclosed |
| US-12370194-B2 | Metalloenzyme inhibitor compounds | EIKONIZO THERAPEUTICS, INC. (US) | 2025-07-29 | — | — | US | disclosed |
| WO-2024128741-A9 | SUBSTITUTED HETEROCYCLIC COMPOUND DERIVATIVES AND THEIR PHARMACEUTICAL USE | AVELOS THERAPEUTICS INC. (KR) | 2025-05-30 | — | — | WO | disclosed |
| US-20240307391-A1 | METALLOENZYME INHIBITOR COMPOUNDS | EIKONIZO THERAPEUTICS, INC. (US) | 2024-09-19 | — | — | US | disclosed |
| EP-3810109-B1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING CD73 | PELOTON THERAPEUTICS INC (US) | 2024-08-07 | — | — | EP | disclosed |
| WO-2024128741-A1 | SUBSTITUTED HETEROCYCLIC COMPOUND DERIVATIVES AND THEIR PHARMACEUTICAL USE | AVELOS THERAPEUTICS INC. (KR) | 2024-06-20 | — | — | WO | disclosed |
| US-11938134-B2 | Metalloenzyme inhibitor compounds | EIKONIZO THERAPEUTICS, INC. (US) | 2024-03-26 | — | — | US | disclosed |
| US-20240067631-A1 | PYRAZOLE DERIVATIVES USEFUL AS NAMPT MODULATORS | CYTOKINETICS, INC. | 2024-02-29 | — | — | US | disclosed |
| US-7618960-B2 | Morpholine type cinnamide compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-11-17 | — | — | US | disclosed |
| WO-2009058298-A1 | P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | MERCK & CO., INC. (US) | 2009-05-07 | — | — | WO | disclosed |
| US-20080287437-A1 | Pyrazolylaminopyrimidine Derivatives Useful as Tyrosine Kinase Inhibitors | ASTRAZENECA AB (SE) | 2008-11-20 | — | — | US | disclosed |
| WO-2008117050-A1 | PYRAZOLYL-AMINO-SUBSTITUTED PYRAZINES AND THEIR USE FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2008-10-02 | — | — | WO | disclosed |
| EP-1953154-A1 | MORPHOLINE TYPE CINNAMIDE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2008-08-06 | — | — | EP | disclosed |
| EP-1899323-A2 | PYRAZOLYLAMINOPYRIMIDINE DERIVATIVES USEFUL AS TYROSINE KINASE INHIBITORS | AstraZeneca AB (SE) | 2008-03-19 | — | — | EP | disclosed |
| EP-1846394-A1 | PYRAZOLYLAMINOPYRIDINE DERIVATIVES USEFUL AS KINASE INHIBITORS | AstraZeneca AB (SE) | 2007-10-24 | — | — | EP | disclosed |
| US-20070117798-A1 | Morpholine type cinnamide compound | EISAI R&D MANAGEMENT CO., LTD. | 2007-05-24 | — | — | US | disclosed |
| WO-2006123113-A2 | PYRAZOLYLAMINOPYRIMIDINE DERIVATIVES USEFUL AS TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2006-11-23 | — | — | WO | disclosed |
| WO-2006082392-A1 | PYRAZOLYLAMINOPYRIDINE DERIVATIVES USEFUL AS KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2006-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240307391-A1 | METALLOENZYME INHIBITOR COMPOUNDS | HDAC6, HDAC1, HDAC2 | APLNR 3242/4885HDAC6 1/4885JAK2 2318/4885 |
| US-20080287437-A1 | Pyrazolylaminopyrimidine Derivatives Useful as Tyrosine Kinase Inhibitors | ABL1, FLT3, ERBB2 | APLNR 3478/4885HDAC6 869/4885JAK2 32/4885 |
| US-20070117798-A1 | Morpholine type cinnamide compound | MLX, XDH, NOX4 | APLNR 3965/4885HDAC6 229/4885JAK2 353/4885 |
| US-20250352549-A1 | SUBSTITUTED HETEROCYCLIC COMPOUND DERIVATIVES AND THEIR PHARMACEUTICAL USE | MAST1, MAST3, MAST4 | APLNR 3775/4885HDAC6 172/4885JAK2 426/4885 |
| US-20240067631-A1 | PYRAZOLE DERIVATIVES USEFUL AS NAMPT MODULATORS | NAMPT, NNT, NAPRT | APLNR 2880/4885HDAC6 41/4885JAK2 1170/4885 |
| US-20260124204-A1 | METALLOENZYME INHIBITOR COMPOUNDS | HDAC6, HDAC3, HDAC1 | APLNR 1631/4885HDAC6 1/4885JAK2 4492/4885 |
| US-11938134-B2 | Metalloenzyme inhibitor compounds | HDAC6, HDAC1, HDAC2 | APLNR 3242/4885HDAC6 1/4885JAK2 2318/4885 |
| US-12370194-B2 | Metalloenzyme inhibitor compounds | HDAC6, HDAC1, HDAC2 | APLNR 3242/4885HDAC6 1/4885JAK2 2318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.